checkAd

PureTech Announces Publication of Glyph Platform Preclinical Proof-of-Concept Study in Journal of Controlled Release

Nachrichtenquelle: Business Wire (engl.)
25.02.2021, 15:17  |  154   |   |   

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced the publication of a research paper in the Journal of Controlled Release. Results provide further preclinical proof-of-concept for PureTech’s Glyph platform technology, which is designed to traffic small molecule therapeutics directly into the lymphatic system via oral administration.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210225005700/en/

PureTech announced the publication of a paper in the Journal of Controlled Release. Results provide further preclinical proof-of-concept for PureTech’s lymphatic targeting technology platform Glyph, which is designed to traffic small molecule therapeutics directly into the lymphatic system via oral administration. (Graphic: Business Wire)

PureTech announced the publication of a paper in the Journal of Controlled Release. Results provide further preclinical proof-of-concept for PureTech’s lymphatic targeting technology platform Glyph, which is designed to traffic small molecule therapeutics directly into the lymphatic system via oral administration. (Graphic: Business Wire)

Results highlighted in the publication demonstrate the ability of a therapeutic modality built from PureTech’s Glyph platform to target administration of mycophenolic acid (MPA), an immunosuppressant, into lymph and directly into gut-draining mesenteric lymph nodes (MLNs). As a key nexus of immune cell trafficking, MLNs play major roles in the pathophysiology of a range of conditions including inflammatory and autoimmune diseases, cancer, and metabolic diseases.

“The Glyph platform has tremendous therapeutic potential for orally administered medicines because it may allow us to bypass first-pass metabolism in the liver and directly target the lymphatic system, which is a critical site for immune cell programming and trafficking. With this study, we have shown that the platform enhances immunomodulation in the mesenteric lymph nodes,” said Christopher Porter, Ph.D., Director of the Monash Institute of Pharmaceutical Sciences at Monash University in Melbourne, lead author of the study and a PureTech collaborator. “This in vivo proof of concept is an excellent foundation for advancing drug development that leverages the Glyph platform.”

Seite 1 von 3
PureTech Health Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de



Diesen Artikel teilen
Wertpapier



0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

PureTech Announces Publication of Glyph Platform Preclinical Proof-of-Concept Study in Journal of Controlled Release PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced …

Nachrichten des Autors

Titel
Titel
Titel
Titel